Step by Step

INTRODUCTION

1/18/24 Anesthesiology GR: Quantity Over Quality: One Institutions Navigation of the Recent Updates in Monitoring and Antagonism of Neuromuscular Blockade

QUIZ

EVALUATION

CERTIFICATE

INTRODUCTION

Credit Hours: CME 1.00

Target Audience:

Anesthesiologists and anesthesiologists-in-training and other anesthesia professionals, nurse anesthetists and anesthesia assistants.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Provide definition and clinical consequences of residual neuromuscular blockade
  • Summarize the recommendations from the 2023 ASA Practice Guidelines for Monitoring and Antagonism of Neuromuscular Blockade
  • Compare methods of monitoring neuromuscular blockade
  • Identify recommended roles of sugammadexvs. neostigmine in neuromuscular blockade reversal
  • Apply best available evidence-based practices to avoid residual paralysis in practice setting

Suggested Additional Reading & Joint Accreditation Statement - Note: This Accreditation Statement Supersedes All Other Statements:

Joint Accreditation Statement:

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


The University of Pittsburgh School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Each physician should only claim credit commensurate with the extent of their participation in the activity. 


Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Suggested Additional Reading

  1. EikermannM, Vogt FM, Herbstreit F, et al. The predisposition to inspiratory upper airway collapse during partial neuromuscular blockade. Am J RespirCritCare Med. 2007;175(1):9-15. 
  2. BlobnerM, Hollmann MW, LuediMM, Johnson KB. Pro-Con Debate: Do We Need Quantitative Neuromuscular Monitoring in the Era of Sugammadex?. AnesthAnalg. 2022;135(1):39-48. 
  3. Fortier LP, McKeenD, Turner K, et al. The RECITE Study: A Canadian Prospective, Multicenter Study of the Incidence and Severity of Residual Neuromuscular Blockade. AnesthAnalg. 2015;121(2):366-372.
  4. SaagerL, MaieseEM, Bash LD, et al. Incidence, risk factors, and consequences of residual neuromuscular block in the United States: The prospective, observational, multicenter RECITE-US study. J ClinAnesth. 2019;55:33-41. 
  5. KotakeY, OchiaiR, Suzuki T, et al. Reversal with sugammadexin the absence of monitoring did not preclude residual neuromuscular block. AnesthAnalg. 2013;117(2):345-351. 
  6. DebaeneB, PlaudB, Dilly MP, DonatiF. Residual paralysis in the PACU after a single intubating dose of nondepolarizingmuscle relaxant with an intermediate duration of action. Anesthesiology. 2003;98(5):1042-1048.
  7. Thilen SR, WeigelWA, Todd MM, et al. 2023 American Society of Anesthesiologists Practice Guidelines for Monitoring and Antagonism of Neuromuscular Blockade: A Report by the American Society of Anesthesiologists Task Force on Neuromuscular Blockade. Anesthesiology. 2023;138(1):13-41. 

Authors:
Chang H. Park, MD — Assistant Professor of Anesthesiology, Perioperative and Pain Medicine| Associate Program Director, Regional Anesthesiology and Acute Pain Medicine Fellowship, Icahn School of Medicine at Mount Sinai
No relationships with industry relevant to the content of this educational activity have been disclosed.
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity is approved for AMA PRA Category 1 Credit™

The University of Pittsburgh is an affirmative action, equal opportunity institution.